Macrogenics (MGNX) risk factors

45 risks, 6 new, 4 dropped, 12 reworded since the prior year. MacroGenics faces a partial clinical hold on the LINNET study after Grade 5 and other severe adverse events. The company relies on third parties for companion diagnostics and CDMO services at its Rockville facility. Employee headcount dropped from 341 to 293 full-time workers.

43 risks. MacroGenics faces significant ongoing financial losses with an accumulated deficit of approximately $1.2 billion and a critical need for substantial additional funding. The company relies heavily on clinical trials for multiple product candidates and key development and commercialization collaborations. Operations are subject to extensive regulatory oversight, intellectual property challenges, and strict healthcare laws.